Similar articles

• Racial disparity in mycosis fungoides: An analysis of 4495 cases from the US National Cancer Database.

  Su C, Nguyen KA, Bai HX, Cao Y, Tao Y, Xiao R, Karakousis G, Zhang PJ, Zhang G. Su C, et al. J Am Acad Dermatol. 2017 Sep;77(3):497-502.e2. doi: 10.1016/j.jaad.2017.04.1137. Epub 2017 Jun 20. J Am Acad Dermatol. 2017. PMID: 28645647
• The Impact of Primary Tumor Site on Survival in Mycosis Fungoides.

  Go CC, Zhong A, Linaburg T, Briceño CA. Go CC, et al. Cutis. 2024 Apr;113(4):177-182. doi: 10.12788/cutis.0991. Cutis. 2024. PMID: 38820109
• The changing survival of patients with mycosis fungoides: a population-based assessment of trends in the United States.

  Jones GW, Wilson LD. Jones GW, et al. Cancer. 1999 Jul 1;86(1):191-3. doi: 10.1002/(sici)1097-0142(19990701)86:1<191::aid-cncr26>3.0.co;2-e. Cancer. 1999. PMID: 10391580 No abstract available.
• Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?

  Scarisbrick JJ, Kim YH, Whittaker SJ, Wood GS, Vermeer MH, Prince HM, Quaglino P. Scarisbrick JJ, et al. Br J Dermatol. 2014 Jun;170(6):1226-36. doi: 10.1111/bjd.12909. Br J Dermatol. 2014. PMID: 24641480 Review.
• Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.

  Hughes CF, Newland K, McCormack C, Lade S, Prince HM. Hughes CF, et al. Australas J Dermatol. 2016 Aug;57(3):182-91. doi: 10.1111/ajd.12349. Epub 2015 May 18. Australas J Dermatol. 2016. PMID: 25988337 Review.